Dianthus Therapeutics, Inc. (DNTH)
NCM · Healthcare · Biotechnology
$104.09
+2.44%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$5.69B
Shares Outstanding
54.7M
P/S (TTM)
4,259x
Exchange
NCM
Currency
USD
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 193K | 396K | 284K | 463K |
| Operating Income | -34.9M | -40.3M | -69.5M | -46.5M |
| Net Income | -31.6M | -36.8M | -64.4M | -40.8M |
| Diluted EPS | $-0.88 | $-0.97 | $-1.43 | $-0.85 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 6.4M | 2.8M | 6.2M | 2.0M |
| Operating Income | -29.7M | -48.2M | -101.9M | -177.9M |
| Net Income | -28.5M | -43.6M | -85.0M | -162.3M |
| Diluted EPS | $-1.92 | $-8.45 | $-2.55 | $nan |